STM Journals Peer-reviewed research from Consortium e-Learning Network

Research and Reviews : A Journal of Life Sciences Original Research

Role of Neuropeptides in the Treatment of Major Depression Disorder: The Recent Updates

  1. Shivani Panwar Department of Biotechnology, Jaypee Institute of Information Technology, Noida
  2. Abhimanyu Chauhan Department of Biotechnology, Jaypee Institute of Information Technology, Noida
  3. Chakresh Kumar Jain Department of Biotechnology, Jaypee Institute of Information Technology, Noida

Abstract

Revelation of the part of neuropeptides as signaling atoms within the nervous system raised trust within the pharmaceutical field approximately 25. long time back Many neuropeptides, especially CRH, AVP, and substance P . whose receptors are presently focused on by little atoms to diminish side effects of discouragement and uneasiness, shows up to be related to the improvement and movement of temperament disarranges trouble. Neurotrophins, not exactly neuropeptides, may also play a unique role in antidepressant activity and are likely characteristic of depression. Neurotensin (NT) is responsible for schizophrenia-like symptoms, adding credence to the idea that drugs that disrupt the NT system may have antipsychotic properties. Finally, neuropeptides could be used to treat sleep disorders. that are currently treated with sleeping pills but have significant side effects. Axel Steiger's research indicates that certain neuropeptides can improve sleep quality, even when administered peripherally. Anxiety and despair have increased in today's culture. This slant contains a colossal affect on people's mental health and in this way contributes essentially to ailment and, within the most exceedingly bad cases, suicide . Despite the availability of several antidepressants and anxiolytics, Morden was unable to bring patients into remission. Because the pathophysiology of anxiety and depression remains largely unknown, researchers have lost focus on neuropeptides; Many unknown studies have turned their attention to neuropeptides, a large class of signaling molecules in the nervous system.

Keywords

References (70)

  1. Kessler RC, et al.; National Comorbidity Survey Replication (2003) The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 289(23):3095–3105.
  2. Wittchen HU, et al. (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21(9):655–679.
  3. de Kloet ER, Joëls M, Holsboer F (2005) Stress and the brain: From adaptation to disease. Nat Rev Neurosci 6(6):463–475
  4. Nestler EJ, et al. (2002) Neurobiology of depression. Neuron 34(1):13–25.
  5. McEwen BS (2008) Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol 583(2-3):174–185.
  6. Labonté B, et al. (2013) Genome-wide methylation changes in the brains of suicide completers. Am J Psychiatry 170(5):511–520.
  7. Vialou V, Feng J, Robison AJ, Nestler EJ (2013) Epigenetic mechanisms of depression and antidepressant action. Annu Rev Pharmacol Toxicol 53:59–87.
  8. Blier P, de Montigny C (1994) Current advances and trends in the treatment of depression Trends Pharmacol Sci 15(7):220–226
  9. Millan MJ (2006) Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic applications. Pharmacol Ther 110(2):135–370.
  10. Wang PS, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Borges G, Bromet EJ, et al. Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO World Mental Health Surveys. Lancet. 2007;370:841–50.
  11. Tatemoto K, Rökaeus Å, Jörnvall H, McDonald TJ, Mutt V. Galanin — a novel biologically active peptide from porcine intestine. FEBS Letters. 1983;164(1):124-128. doi:10.1016/0014-5793(83)80033-7
  12. RC Kessler, et al., The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA; National Comorbidity Survey Replication 289, 3095–3105(2003).
  13. HU Wittchen, et al., The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol21, 655–679 (2011).
  14. ER de Kloet, M Joëls, F Holsboer, Stress, and the brain: From adaptation to disease. Nat Rev Neurosci 6, 463–475 (2005).
  15. Kormos V, Gaszner B. Role of neuropeptides in anxiety, stress, and depression: From animals to humans. Neuropeptides. 2013;47(6):401-419. doi:10.1016/j.npep.2013.10.014
  16. Rana T, Behl T, Sehgal A, Singh S, Sharma N, Abdeen A, et al. Exploring the role of neuropeptides in depression and anxiety. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2022;114:110478. doi:10.1016/j.pnpbp.2021.110478
  17. Hoyer D, Bartfai T. Neuropeptides and Neuropeptide Receptors: Drug Targets, and Peptide and Non‐Peptide Ligands: a Tribute to Prof.Dieter Seebach. Chemistry & Biodiversity. 2012;9(11):2367-2387. doi:10.1002/cbdv.201200288
  18. OMIM—Online Mendelian Inheritance in Man, OMIM® McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD, USA). 25 May 2022. [(accessed on 3 June 2022)]. Available online: https://omim.org/ [Ref list]
  19. Lach G, Schellekens H, Dinan TG, Cryan JF. Anxiety, Depression, and the Microbiome: A Role for Gut Peptides. Neurotherapeutics. 2018;15(1):36-59. doi:10.1007/s13311-017-0585-0
  20. Miller WL. The Hypothalamic-Pituitary-Adrenal Axis: A Brief History. Hormone Research in Paediatrics. 2018;89(4):212-223. doi:10.1159/000487755
  21. Daskalakis NP, Meijer OC, de Kloet ER. Mineralocorticoid receptor and glucocorticoid receptor work alone and together in cell-type-specific manner: Implications for resilience prediction and targeted therapy. Neurobiology of Stress. 2022;18:100455. doi:10.1016/j.ynstr.2022.100455
  22. Belvederi Murri M, Pariante C, Mondelli V, Masotti M, Atti AR, Mellacqua Z, et al. HPA axis and aging in depression: Systematic review and meta-analysis. Psychoneuroendocrinology. 2014;41:46-62. doi:10.1016/j.psyneuen.2013.12.004
  23. Belvederi Murri M, Prestia D, Mondelli V, Pariante C, Patti S, Olivieri B, et al. The HPA axis in bipolar disorder: Systematic review and meta-analysis. Psychoneuroendocrinology. 2016;63:327-342. doi:10.1016/j.psyneuen.2015.10.014
  24. Juruena MF, Bocharova M, Agustini B, Young AH. Atypical depression and non-atypical depression: Is HPA axis function a biomarker? A systematic review. Journal of Affective Disorders. 2018;233:45-67. doi:10.1016/j.jad.2017.09.052
  25. Petra AI, Panagiotidou S, Hatziagelaki E, Stewart JM, Conti P, Theoharides TC. Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation. Clinical Therapeutics. 2015;37(5):984-995. doi:10.1016/j.clinthera.2015.04.002
  26. Rieder R, Wisniewski PJ, Alderman BL, Campbell SC. Microbes and mental health: A review. Brain, Behavior, and Immunity. 2017;66:9-17. doi:10.1016/j.bbi.2017.01.016
  27. Huo R, Zeng B, Zeng L, Cheng K, Li B, Luo Y, et al. Microbiota Modulate Anxiety-Like Behavior and Endocrine Abnormalities in Hypothalamic-Pituitary-Adrenal Axis. Frontiers in Cellular and Infection Microbiology. 2017;7. doi:10.3389/fcimb.2017.00489
  28. Frankiensztajn LM, Elliott E, Koren O. The microbiota and the hypothalamus-pituitary-adrenocortical (HPA) axis, implications for anxiety and stress disorders. Current Opinion in Neurobiology. 2020;62:76-82. doi:10.1016/j.conb.2019.12.003
  29. Juruena M.F., Eror F., Cleare A.J., Young A.H. The Role of Early Life Stress in HPA axis and Anxiety. In: Kim Y.-K., editor. Anxiety Disorders. Volume 1191. Advances in Experimental Medicine and Biology; Springer; Singapore: 2020. pp. 141–153. [PubMed] [Google Scholar]
  30. Mohapatra SS, Mukherjee J, Banerjee D, Das PK, Ghosh PR, Das K. RFamide peptides, the novel regulators of mammalian HPG axis: A review. Veterinary World. 2021:1867-1873. doi:10.14202/vetworld.2021.1867-1873
  31. Johnson MA, Tsutsui K, Fraley GS. Rat RFamide-related peptide-3 stimulates GH secretion, inhibits LH secretion, and has variable effects on sex behavior in the adult male rat. Hormones and Behavior. 2007;51(1):171-180. doi:10.1016/j.yhbeh.2006.09.009
  32. Kirby ED, Geraghty AC, Ubuka T, Bentley GE, Kaufer D. Stress increases putative gonadotropin inhibitory hormone and decreases luteinizing hormone in male rats. Proceedings of the National Academy of Sciences. 2009;106(27):11324-11329. doi:10.1073/pnas.0901176106
  33. Ubuka T, Mizuno T, Fukuda Y, Bentley GE, Wingfield JC, Tsutsui K. RNA interference of gonadotropin-inhibitory hormone gene induces aggressive and sexual behaviors in birds. General and Comparative Endocrinology. 2013;181:179-186. doi:10.1016/j.ygcen.2012.09.010
  34. Iwasa T, Matsuzaki T, Yano K, Irahara M. Gonadotropin-Inhibitory Hormone Plays Roles in Stress-Induced Reproductive Dysfunction. Frontiers in Endocrinology. 2017;8. doi:10.3389/fendo.2017.00062
  35. Suszka‐Świtek A, Pałasz A, Filipczyk Ł, Menezes IC, Mordecka‐Chamera K, Angelone T, et al. The GnRH analogues affect novel neuropeptide SMIM20/phoenixin and GPR173 receptor expressions in the female rat hypothalamic–pituitary–gonadal (HPG) axis. Clinical and Experimental Pharmacology and Physiology. 2019;46(4):350-359. doi:10.1111/1440-1681.13061
  36. Young, 3rd WS, Gainer H. Transgenesis and the Study of Expression, Cellular Targeting and Function of Oxytocin, Vasopressin and Their Receptors. Neuroendocrinology. 2003;78(4):185-203. doi:10.1159/000073702
  37. Caldwell HK, Lee HJ, Macbeth AH, Young WS. Vasopressin: Behavioral roles of an “original” neuropeptide. Progress in Neurobiology. 2008;84(1):1-24. doi:10.1016/j.pneurobio.2007.10.007
  38. Zheng H, Lim JY, Kim Y, Jung ST, Hwang SW. The role of oxytocin, vasopressin, and their receptors at nociceptors in peripheral pain modulation. Frontiers in Neuroendocrinology. 2021;63:100942. doi:10.1016/j.yfrne.2021.100942
  39. Neumann ID, Landgraf R. Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends in Neurosciences. 2012;35(11):649-659. doi:10.1016/j.tins.2012.08.004
  40. Hodgson RA, Mullins D, Lu SX, Guzzi M, Zhang X, Bleickardt CJ, et al. Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior. European Journal of Pharmacology. 2014;730:157-163. doi:10.1016/j.ejphar.2014.02.027
  41. Rocha A., Godino-Gimeno A., Cerdá-Reverter J.M. Vitamins and Hormones.Volume 111. Elsevier; Amsterdam, The Netherlands: 2019. Evolution of Proopiomelanocortin; pp. 1–16. [PubMed] [Google Scholar]
  42. Fosgerau K, Raun K, Nilsson C, Dahl K, Wulff BS. Novel α-MSH analog causes weight loss in obese rats and minipigs and improves insulin sensitivity. Journal of Endocrinology. 2013;220(2):97-107. doi:10.1530/joe-13-0284
  43. Gargiulo AT, Curtis GR, Barson JR. Pleiotropic pituitary adenylate cyclase-activating polypeptide (PACAP): Novel insights into the role of PACAP in eating and drug intake. Brain Research. 2020;1729:146626. doi:10.1016/j.brainres.2019.146626
  44. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, et al. Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery. Pharmacological Reviews. 2009;61(3):283-357. doi:10.1124/pr.109.001370
  45. Stojakovic A, Ahmad SM, Malhotra S, Afzal Z, Ahmed M, Lutfy K. The role of pituitary adenylyl cyclase-activating polypeptide in the motivational effects of addictive drugs. Neuropharmacology. 2020;171:108109. doi:10.1016/j.neuropharm.2020.108109
  46. Liao C, de Molliens MP, Schneebeli ST, Brewer M, Song G, Chatenet D, et al. Targeting the PAC1 Receptor for Neurological and Metabolic Disorders. Current Topics in Medicinal Chemistry. 2019;19(16):1399-1417. doi:10.2174/1568026619666190709092647
  47. Redrobe JP, Dumont Y, Quirion R. Neuropeptide Y (NPY) and depression: From animal studies to the human condition. Life Sciences. 2002;71(25):2921-2937. doi:10.1016/s0024-3205(02)02159-8
  48. Widerlöv E, Lindström LH, Wahlestedt C, Ekman R. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. Journal of Psychiatric Research. 1988;22(1):69-79. doi:10.1016/0022-3956(88)90030-1
  49. Morales-Medina JC, Dumont Y, Quirion R. A possible role of neuropeptide Y in depression and stress. Brain Research. 2010;1314:194-205. doi:10.1016/j.brainres.2009.09.077
  50. Holzer P, Reichmann F, Farzi A. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut–brain axis. Neuropeptides. 2012;46(6):261-274. doi:10.1016/j.npep.2012.08.005
  51. Cheng Y, Tang XY, Li YX, Zhao DD, Cao QH, Wu HX, et al. Depression-Induced Neuropeptide Y Secretion Promotes Prostate Cancer Growth by Recruiting Myeloid Cells. Clinical Cancer Research. 2019;25(8):2621-2632. doi:10.1158/1078-0432.ccr-18-2912
  52. Hassan AM, Mancano G, Kashofer K, Fröhlich EE, Matak A, Mayerhofer R, et al. High-fat diet induces depression-like behaviour in mice associated with changes in microbiome, neuropeptide Y, and brain metabolome. Nutritional Neuroscience. 2018;22(12):877-893. doi:10.1080/1028415x.2018.1465713
  53. Domin H. Neuropeptide Y Y2 and Y5 receptors as potential targets for neuroprotective and antidepressant therapies: Evidence from preclinical studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2021;111:110349. doi:10.1016/j.pnpbp.2021.110349
  54. Carboni L, El Khoury A, Beiderbeck DI, Neumann ID, Mathé AA. Neuropeptide Y, calcitonin gene-related peptide, and neurokinin A in brain regions of HAB rats correlate with anxiety-like behaviours. European Neuropsychopharmacology. 2022;57:1-14. doi:10.1016/j.euroneuro.2021.12.011
  55. Sharma A, Ren X, Zhang H, Pandey GN. Effect of depression and suicidal behavior on neuropeptide Y (NPY) and its receptors in the adult human brain: A postmortem study. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2022;112:110428. doi:10.1016/j.pnpbp.2021.110428
  56. Wegener G, Finger BC, Elfving B, Keller K, Liebenberg N, Fischer CW, et al. Neuropeptide S alters anxiety, but not depression-like behaviour in Flinders Sensitive Line rats: a genetic animal model of depression. The International Journal of Neuropsychopharmacology. 2011;15(03):375-387. doi:10.1017/s1461145711000678
  57. Okamura N, Hashimoto K, Iyo M, Shimizu E, Dempfle A, Friedel S, et al. Gender-specific association of a functional coding polymorphism in the Neuropeptide S receptor gene with panic disorder but not with schizophrenia or attention-deficit/hyperactivity disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2007;31(7):1444-1448. doi:10.1016/j.pnpbp.2007.06.026
  58. Raiteri L, Luccini E, Romei C, Salvadori S, Calò G. Neuropeptide S selectively inhibits the release of 5‐HT and noradrenaline from mouse frontal cortex nerve endings. British Journal of Pharmacology. 2009;157(3):474-481. doi:10.1111/j.1476-5381.2009.00163.x
  59. Gupta PR, Prabhavalkar K. Combination therapy with neuropeptides for the treatment of anxiety disorder. Neuropeptides. 2021;86:102127. doi:10.1016/j.npep.2021.102127
  60. Tillmann S, Skibdal HE, Christiansen SH, Gøtzsche CR, Hassan M, Mathé AA, et al. Sustained overexpression of neuropeptide S in the amygdala reduces anxiety-like behavior in rats. Behavioural Brain Research. 2019;367:28-34. doi:10.1016/j.bbr.2019.03.039
  61. Gouardères C, Sutak M, Zajac JM, Jhamandas K. Antinociceptive effects of intrathecally administered F8Famide and FMRFamide in the rat. European Journal of Pharmacology. 1993;237(1):73-81. doi:10.1016/0014-2999(93)90095-y
  62. Fehmann HC, McGregor G, Weber V, Eissele R, Göke R, Göke B, et al. The effects of two FMRFamide related peptides (A-18-F-amide and F-8-F-amide; ‘morphine modulating peptides’) on the endocrine and exocrine rat pancreas. Neuropeptides. 1990;17(2):87-92. doi:10.1016/0143-4179(90)90054-3
  63. Nguyen T, Marusich J, Li JX, Zhang Y. Neuropeptide FF and Its Receptors: Therapeutic Applications and Ligand Development. Journal of Medicinal Chemistry. 2020;63(21):12387-12402. doi:10.1021/acs.jmedchem.0c00643
  64. Kim JS. What's in a Name? Roles ofRFamide‐Related Peptides Beyond Gonadotrophin Inhibition. Journal of Neuroendocrinology. 2016;28(9). doi:10.1111/jne.12407
  65. Lin YT, Yu YL, Hong WC, Yeh TS, Chen TC, Chen JC. NPFFR2 Activates the HPA Axis and Induces Anxiogenic Effects in Rodents. International Journal of Molecular Sciences. 2017;18(8):1810. doi:10.3390/ijms18081810
  66. Bondy B, Baghai TC, Minov C, Schüle C, Schwarz MJ, Zwanzger P, et al. Substance P serum levels are increased in major depression: preliminary results. Biological Psychiatry. 2003;53(6):538-542. doi:10.1016/s0006-3223(02)01544-5
  67. Iftikhar K, Siddiq A, Baig SG, Zehra S. Substance P: A neuropeptide involved in the psychopathology of anxiety disorders. Neuropeptides. 2020;79:101993. doi:10.1016/j.npep.2019.101993
  68. Schwarz MJ, Ackenheil M. The role of substance P in depression: therapeutic implications. Dialogues in Clinical Neuroscience. 2002;4(1):21-29. doi:10.31887/dcns.2002.4.1/mschwarz
  69. Borbély É, Hajna Z, Nabi L, Scheich B, Tékus V, László K, et al. Hemokinin-1 mediates anxiolytic and anti-depressant-like actions in mice. Brain, Behavior, and Immunity. 2017;59:219-232. doi:10.1016/j.bbi.2016.09.004
  70. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, et al. Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression. Neuropsychopharmacology. 2003;29(2):385-392. doi:10.1038/sj.npp.1300260
Support